Core Viewpoint - The company has announced a downward adjustment of the conversion price for its convertible bonds, "Lingkang Convertible Bonds," from 8.00 CNY to 6.50 CNY per share, effective from August 1, 2025, due to the stock price being below the current conversion price for a significant period [1][5][6] Summary by Sections 1. Securities Suspension and Resumption - The company's securities will be suspended from conversion starting July 31, 2025, and will resume on August 1, 2025 [1][6] 2. Basic Information on Convertible Bonds - The company issued 5.25 million convertible bonds on December 1, 2020, with a total value of 525 million CNY and a maturity of 6 years [1][2] 3. Adjustment of Conversion Price - The initial conversion price was set at 8.81 CNY per share, later adjusted to 8.00 CNY per share. The latest adjustment reduces it to 6.50 CNY per share [2][5] 4. Triggering Conditions for Price Adjustment - The adjustment was triggered as the company's stock price was below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [5] 5. Approval Process for Price Adjustment - The board of directors approved the price adjustment on July 14, 2025, and a special resolution was passed at the shareholders' meeting on July 30, 2025, authorizing the board to implement the adjustment [5][6]
灵康药业: 关于向下修正“灵康转债”转股价格暨转股停复牌的公告